Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Trending
- Who owns the billions in Germany’s dormant bank accounts?
- Several soldiers killed in Israeli strike on Lebanon
- Pope Leo XIV calls for national reconciliation on his first day in Spain
- Emilia Clarke, Edgar Ramirez Lead Romantic Drama
- ‘Dreams of Violets’ AI-generated film to debut at Tribeca Film Festival
- Airline chiefs grapple with fuel shock, fare test at Rio summit
- Anthropic urges AI labs to pause, warns humans risk losing control | Technology News
- Advice service demand rises amid housing crisis
